Gyre Therapeutics (GYRE) Retained Earnings (2010 - 2026)
Gyre Therapeutics (GYRE) reported Retained Earnings of -$77.7 million for Q1 2026, down 9.7% year-over-year from -$86.0 million in Q1 2025, and down 13.51% on a QoQ basis from -$68.4 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Retained Earnings data on file, last reported at -$77.7 million in Q1 2026.
- Quarterly Retained Earnings fell 9.7% year-over-year to -$77.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.7 million (down 9.7% YoY) and the FY2025 annual result came in at -$68.4 million, down 2534.81% from the prior year.
- Retained Earnings retreated to -$77.7 million in Q1 2026 per GYRE's latest filing, from -$68.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $7.4 million in Q4 2022 and bottomed at -$417.2 million in Q1 2022.
- The 5-year median for Retained Earnings is -$74.5 million (2024), against an average of -$170.6 million.
- Peak annual rise in Retained Earnings reached 101.84% in 2022, while the deepest fall reached 37048300.0% in 2022.
- Tracing GYRE's Retained Earnings over 5 years: stood at $7.4 million in 2022, then slumped by 122.23% to -$1.6 million in 2023, then tumbled by 57.97% to -$2.6 million in 2024, then plunged by 2534.81% to -$68.4 million in 2025, then slipped by 13.51% to -$77.7 million in 2026.
- Per Business Quant, the three latest GYRE Retained Earnings figures stand at -$77.7 million (Q1 2026), -$68.4 million (Q4 2025), and -$66.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -77.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.67 Mn |
| Dec 31, 2025 | -68.43 Mn |
| Sep 30, 2025 | -66.70 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Mar 31, 2025 | -70.80 Mn |
| Dec 31, 2024 | -2.60 Mn |
| Sep 30, 2024 | -73.40 Mn |
| Jun 30, 2024 | -74.50 Mn |
| Mar 31, 2024 | -78.00 Mn |
| Dec 31, 2023 | -1.64 Mn |
| Sep 30, 2023 | -414.70 Mn |
| Jun 30, 2023 | -413.15 Mn |
| Mar 31, 2023 | -410.68 Mn |
| Dec 31, 2022 | 7.40 Mn |
| Sep 30, 2022 | -370.48 Mn |
| Jun 30, 2022 | -365.60 Mn |
| Mar 31, 2022 | -417.20 Mn |
| Dec 31, 2021 | -402.69 Mn |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | -357.10 Mn |
| Mar 31, 2021 | 5,000.00 |
| Dec 31, 2020 | -314.76 Mn |
| Sep 30, 2020 | -295.85 Mn |
| Jun 30, 2020 | -279.82 Mn |
| Mar 31, 2020 | 140,000.00 |
| Dec 31, 2019 | -258.52 Mn |
| Sep 30, 2019 | -244.91 Mn |
| Jun 30, 2019 | -232.20 Mn |
| Mar 31, 2019 | -218.43 Mn |
| Dec 31, 2018 | -4,000.00 |
| Sep 30, 2018 | -192.51 Mn |
| Jun 30, 2018 | -184.81 Mn |
| Mar 31, 2018 | -178.33 Mn |
| Dec 31, 2017 | -173.49 Mn |
| Sep 30, 2017 | 4,000.00 |
| Jun 30, 2017 | -161.95 Mn |
| Mar 31, 2017 | -152.12 Mn |
| Dec 31, 2016 | -1,000.00 |
| Sep 30, 2016 | 4,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Mar 31, 2016 | 4,000.00 |
| Dec 31, 2015 | -131.04 Mn |
| Sep 30, 2015 | -125.91 Mn |
| Jun 30, 2015 | -324.34 Mn |
| Mar 31, 2015 | 23,000.00 |
| Dec 31, 2014 | -116.28 Mn |
| Sep 30, 2014 | 55,000.00 |
| Jun 30, 2014 | 110,000.00 |
| Mar 31, 2014 | -295.63 Mn |
| Dec 31, 2013 | 87,000.00 |
| Sep 30, 2013 | 95,000.00 |
| Jun 30, 2013 | -254.37 Mn |
| Mar 31, 2013 | -241.99 Mn |
| Dec 31, 2012 | -233.93 Mn |
| Sep 30, 2012 | 377,000.00 |
| Jun 30, 2012 | 194,000.00 |
| Mar 31, 2012 | 227,000.00 |
| Dec 31, 2011 | -226.93 Mn |
| Sep 30, 2011 | -19,000.00 |
| Jun 30, 2011 | -208.07 Mn |
| Dec 31, 2010 | 225,000.00 |